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(1) HCCs commonly arise amidst an intricate crosstalk between cancer, angiogenic, inflammatory, and fibroblastic cells in a hypoxic milieu that fosters tumor growth. (2) HCCs are molecularly heterogeneous tumors, (3) and this heterogeneity may underlie the limited success of conventional and targeted chemotherapies tested in HCC patients, (1) with systemic treatment options currently limited to the multikinase inhibitors sorafenib and regorafenib. (4, 5) Although these agents do improve patients' survival, therapies targeting growth factor signaling have shown limited success, (1) and novel approaches for HCC treatment must be pursued. The promising results of emerging immunotherapies illustrate the potential of exploring alternative avenues for HCC treatment. (6) Up to 50% of HCCs harbor alterations in the epigenetic machineries, suggesting a profound reshape in the epigenome as a hallmark of HCC. (7) Global genomic DNA hypomethylation is characteristic of HCC. This is accompanied by locus-specific hypermethylation and silencing of putative tumor suppressor genes in association with abnormal expression of the DNA methyltransferases DNMT1, DNMT3a, and DNMT3b. (8) These alterations contribute to the pathogenesis and prognosis of HCC from early stages of the disease, (9) and targeting aberrant DNA methylation using DNMT inhibitors is currently being explored. (10) Other epigenetic alterations found in HCC include reversible changes in the posttranslational modification of histones, such as acetylation or methylation of lysine residues, which may occur in genome-wide and gene-specific manners. (8) Dysregulation of histone-modifying enzymes such as histone deacetylases (HDACs) and histone methyltransferases (HMTs) has been also reported in HCC, with elevated expression of class I and III HDACs, and HMTs such as enhancer of zeste homolog-2 (EZH2), affecting HCC progression. (8, 11) Some drugs targeting these epigenetic modifiers have been tested in clinical trials with promising results. (12) However, epigenetic regulation is a complex process with different effectors, such as DNMTs and HMTs, cooperating in chromatin remodeling and gene expression control. (13) In this sense, several studies have shown how DNA methylation and histone H3 methylation at lysine 9 (H3K9) engage in an epigenetic conversation in which methylation information is ''translated'' from histone to DNA and vice versa. (13, 14) H3K9 mono-and di-methylation is catalyzed by the HMT G9a, also known as euchromatic histonelysine methyltransferase 2 (EHMT2). (15) G9a physically interacts with DNMT1, contributing to DNA methylation during cell replication. (16) G9a expression is dysregulated in cancer, contributing to cell growth, survival, adaptation to hypoxia, and metastasis. (15) Very recently, G9a was shown to be up-regulated and to promote HCC progression. (17) In agreement with the functional interaction between DNMT1 and G9a, both DNA and H3K9 methylation have been linked to tumor suppressor gene silencing and cancer cell proliferation. (18) Therefore, we hypothesized that simultaneous targeting of G9a and DNMT methyltransferase activity could be a more effective strategy in HCC therapy.
We recently reported the development of potent, selective, and reversible dual small molecule inhibitors against G9a and DNMT activity, demonstrating their efficacy in hematological malignancies. (19) Here we show the potential therapeutic value of this type of molecule in experimental models of HCC.
Materials and Methods

HuMaN saMples
A cohort of 268 liver tumor samples (T), 154 peritumoral liver samples (NT), and 5 samples of normal liver tissues were collected from patients surgically treated in Bordeaux and Créteil hospitals in France. The study was approved by institutional review board committees (CCPRB Paris Saint-Louis, 1997, 2004, and 2010, #01-037; Bordeaux #2010-A00498-31). Written informed consent was obtained in accordance with French legislation. These patients and samples have been described previously (20) (21) (22) and are summarized in Supporting Table S1 . , mice (n = 6) were randomized into control and treatment groups. Orthotopic xenografts are described in the Supporting Materials and Methods. Mice received 5 mg/kg (i.p.) of CM-272 or same volume of vehicle (phosphate-buffered saline [PBS]) for the indicated times. This dose was selected based on our previous studies. (19) At the end of treatment, tumors were harvested, fixed with 4% formalin for histological analyses or snap-frozen, and stored at −80°C.
Mouse XeNograFt MoDels
cell lINes aND HuMaN HepatIc stellate cells
The origin and culture of the 32 HCC cell lines used in this study has been previously described. (23) The human hepatic stellate cell (hHSC) line LX2 (Millipore-Merck, Darmstadt, Germany), was cultured in DMEM supplemented with 2% fetal bovine serum and antibiotics. Primary hHSCs were isolated from resected liver wedges obtained from patients undergoing surgery at the Royal Free Hospital (London, United Kingdom) after giving informed consent (#EC01.14-RF). Isolation, purity, and culture of hHSCs were as published. (24) Experiments were performed on hHSCs from at least 3 independent cell preparations, used between passages 3 and 8. For hypoxic culture conditions, cells were incubated under 1% O 2 atmosphere in the H35 Hypoxystation incubator (Don Whitley Scientific Ltd., Shipley, United Kingdom).
cell prolIFeratIoN assay
Cells were seeded at a density of 2500 to 3000 cells per well in 96-well plates (triplicates). After overnight incubation, cells were treated for 48 hours with vehicle alone (0.1% dimethylsulfoxide) or with CM-272 in complete medium. Experiments were repeated 3 times for each cell line. Cell viability was measured using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, Wisconsin). The concentration of drug inhibiting cell growth by 50% relative to the untreated control (GI 50 ) was calculated after curve fitting with GraphPad-Prism-v5 software as described. (19) 
coMBINatIoN assays
For the calculation of combination index (CI) values, growth inhibition was determined at different concentrations of the G9a inhibitor (BIX-01294) in combination with different concentrations of the DNMT inhibitor decitabine (5-aza-2′-deoxycytidine) (Sigma, St. Louis, Missouri). Briefly, 3000 cells were cultured in a 96-well plate in triplicates, and the different concentrations of compounds were added in a final volume of 100 μL. After 48 hours, viability was measured using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. Data were analyzed using the Calcusyn software (Biosoft, Cambridge, United Kingdom), (19) and the CI determined whether the effects of drug combinations were additive (CI = 1) or synergistic (CI < 1).
statIstIcal aNalysIs
Data visualization and statistical analyses of human samples were performed using R software version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org) and Bioconductor packages. Comparison of the different gene expression levels between groups were evaluated using the MannWhitney U test or Kruskal-Wallis test. Spearman correlation analysis was used to test the association between continuous variables. Univariate survival analysis was performed using a Kaplan-Meier curve with log-rank test. The median G9a, DNMT1, and ubiquitin-like with PHD and RING finger domains 1 (UHRF1) expression levels on the total number of analyzed samples was used to determine the low-and high-expression groups. For the rest of the data, the statistical analysis was performed using GraphPad Prism-v5. For comparison between 2 groups, a parametric Student t test was used. All reported P values were 2-tailed, and differences were considered significant when P < 0.05.
Additional methods are provided as Supporting Materials and Methods.
Results
eXpressIoN oF g9a, DNMt1 aND tHe DNa MetHylatIoN regulator uHrF1 IN HuMaN Hcc
We first examined the expression of G9a and DNMT1 in normal liver tissues (n = 5), peritumor nontransformed liver tissues (NT, n = 154) and tumor liver tissues (T, n = 268) (Supporting Table S1 ). Consistent with recent (17) and previous observations, (25) G9a and DNMT1 expression was significantly elevated in HCC tissues (Fig. 1A) . UHRF1 is an essential regulator of DNA methylation during DNA replication and an adaptor in the crosstalk between DNA and histone methylation, overexpressed in many tumors, including HCCs. (16, 26) We also found high messenger RNA (mRNA) levels of UHRF1 in our HCC samples (Fig.  1A) . Notably, we observed a significant positive correlation between the expression of G9a and DNMT1, G9a and UHRF1, and DNMT1 and UHRF1 across HCC samples (Fig. 1B) . Some of us recently described a molecular signature based on the expression of 5 genes that accurately identified patients with aggressive tumors and a poor prognosis. (27) We found that G9a, DNMT1, and UHRF1 expression was significantly higher in HCC tissues from patients classified by this signature as having a poor prognosis (group P2) (Fig.  1C) . Previous transcriptomic analyses classified HCCs in 6 subgroups, G1 to G6, with worse survival for patients within subgroups G1 to G3. (28) We found the highest levels of G9a, DNMT1, and UHRF1 expression in samples within groups G1 to G3 (Fig. 1C) . G9a, DNMT1, and UHRF1 expression was also higher in HCC tissues displaying macroscopic vascular invasion and in patients with more advanced Edmondson grades and "tumor, node, metastasis" (TNM) stages (Fig. 1C) . Finally, patients with high G9a and DNMT1 mRNA levels showed worse survival, and a similar trend was observed for UHRF1 (Fig. 1D ).
Dual targetINg oF g9a aND DNMt1 IN Hcc cells IN VItro aND IN VIVo
We examined G9a, DNMT1, and UHRF1 expression in a wide panel of human HCC cell lines, finding significantly higher levels compared with normal and peritumoral liver tissues ( Fig. 2A) . G9a, DNMT1, and UHRF1 protein levels were consistently higher in 4 representative HCC cell lines compared with primary human hepatocytes (Fig.  2B) . Interestingly, we also found a significant positive correlation between G9a and DNMT1 mRNA levels and between UHRF1 and DNMT1 mRNA levels, while the correlation between G9a and UHRF1 showed a positive trend (Fig. 2C ). To demonstrate that simultaneous inhibition of G9a and DNMT1 could be an improved strategy to quell HCC cell growth, we tested the effect of G9a and DNMT1 gene expression knockdown on HCC cell viability. Transfection with silencing RNAs (siRNAs) specific for G9a or DNMT1 (Supporting Fig. S1 ) reduced HepG2 and PLC/PRF5 cells survival, and the combinatory effect of both siRNAs was additive (Fig. 2D) . Next, we treated HepG2 and PLC/ PRF5 cells with a G9a inhibitor (BIX-01294) and the DNMT inhibitor Decitabine. This combination showed a synergistic inhibition on HCC cells growth at all concentrations tested (Fig. 2E) . We subsequently evaluated the antiproliferative effects of CM-272, our lead G9a/DNMT1 inhibitory compound, (19) in a panel of HCC cell lines. CM-272 GI 50 was in the nM range for most HCC cell lines (Fig. 3A) . Interestingly, the observed GI 50 values directly correlated with the expression of ABCB1 (Supporting Fig. S2A ), the gene coding for the drug efflux pump Multidrug Resistance 1 (MDR1), a major determinant of tumor cells drug sensitivity. The relevance of this finding was supported by the demonstration that CM-272 is indeed a substrate of MDR1 (Supporting Fig. S2B ). CM-272 decreased total levels of H3K9me2 and DNA methylation (5-methyl-cytosine [5meC]) (Fig. 3B) , while other epigenetic histone marks were not inhibited (Supporting Fig. S2C ). Interestingly, a significant reduction of G9a, DNMT1, and UHRF1 protein levels was found in CM-272-treated cells (Fig. 3B) . However, at the mRNA level this effect was only observed for UHRF1 in HepG2 cells (Supporting Fig. S2D ). CM-272 also markedly impaired the clonogenic capacity of HCC cells (Fig. 3C) .
Next, we examined the in vivo antitumoral properties of CM-272. PLC/PRF5 cells were subcutaneously injected into nude mice, and, when tumors reached 100 mm 3 , mice were treated with CM-272. Tumor growth was significantly reduced, and tumor weights at the end of treatment were also lower (Fig. 3D) . Similar results were obtained in HepG2 subcutaneous xenografts (Supporting Fig. S3A) , and on the growth of PLC/PRF5 cells orthotopically implanted in the livers of nude mice (Fig. 3E, Supporting Fig. S4A ). In agreement with our previous study, (19) we did not observe any signs of toxicity in CM-272 treated animals (Supporting Fig. S3B and C) , and mice weights were normal at the end of treatment (data not shown). Interestingly, serum CM-272 concentrations in treated mice were in the range of its GI 50 as determined at the end of treatments (Supporting Fig. S4B ).
MecHaNIsMs oF cM-272 aNtItuMoral actIVIty IN Hcc cells
To gain insight into the mechanisms of the antitumoral effect of CM-272, we performed a microarray analysis of gene expression in HepG2 cells. We detected 388 upregulated and 509 downregulated genes compared with controls (P < 0.01). Gene ontology (GO) functional classification of differentially expressed genes identified general categories linked to the regulation of cell growth and proliferation and to the interaction with the cellular microenvironment (Fig. 4A) . Microarray gene expression data scrutiny using gene-set enrichment analysis (GSEA) revealed categories related to cell proliferation, metastasis, growth factor signaling, hypoxic response, and interaction with the microenvironment (Supporting Table S3 ), showing negative enrichment in cells treated with CM-272. Among these gene sets we found signatures characteristic of more aggressive HCC subclasses, such as the G1 to G3 subgroups identified by Boyault el al., (28) and the S2 subclass from Hoshida et al. (29) (Fig. 4B) . Remarkably, one of the gene sets with strong positive enrichment encompassed the genes defining the human liver-specific transcriptome, abundant in metabolic genes (30) (Fig. 4B ). These findings suggested that enhanced G9a and DNMT1 activities contribute to the growth of HCC cells and to their interaction with the extracellular milieu, but also evidenced their strong negative impact on the expression of metabolic genes characteristic of the differentiated hepatocyte. Consistently, we found that treatment of HepG2 cells with CM-272 resulted in the upregulation of the epithelial marker E-cadherin (E-CAD). (31) Similarly, the enzymes cholesterol 7α-hydroxylase-1 (CYP7A1), fructose-1,6-bisphosphatase (FBP1), glycine-N-methyl transferase (GNMT), and methionine-adenosyltransferase 1A (MAT1A), involved in key liver metabolic functions, were also induced (Fig. 4C) . Quantitative chromatin immunoprecipitation (qChIP) analyses showed a decrease in H3K9me2 levels in GNMT, CYP7A1, and FBP1 genes promoters upon CM-272 treatment (Fig. 4D) . FBP1, the rate-limiting enzyme in gluconeogenesis, is a tumor suppressor gene, and its expression is reduced in HCC (Supporting Fig. S5A ) in association with molecular and clinical characteristics of tumor aggressiveness (Supporting Fig. S5B ) as previously described. Interestingly, we found a statistically significant negative correlation between FBP1 and G9a or UHRF1 mRNA levels in our set of HCC samples, and a similar trend with DNMT1 mRNA levels (Supporting Fig. S5C ). Downregulation of FBP1 expression is attributed to promoter hypermethylation. (32) Consistently, we observed loss of DNA methylation in FBP1 promoter region after CM-272 or Decitabine treatment, as analyzed by methylation-specific PCR (MSP) or DNA pyrosequencing (Fig. 4E) . The efficacy of CM-272 on DNA demethylation was also validated on RASSF1 (Supporting Fig. S5D ), another gene frequently hypermethylated in HCC. (9) Reduced FBP1 expression stimulates tumor progression by enhancing glucose metabolism to lactate, (32) a process known as aerobic glycolysis, which provides selective advantages for cancer cell proliferation.
(33) Interestingly, we found that CM-272 reduced glucose consumption and lactate production in HepG2 cells (Fig. 4F) .
cM-272 INHIBIts tHe groWtH aND MetaBolIc aDaptatIoN oF Hcc cells to HypoXIa
In solid tumors such as HCC, glycolysis is exacerbated by the protumorigenic hypoxic environment. (34) As recently found in breast cancer cells, (35) we observed that G9a protein levels were increased in HCC cells under hypoxia ( Fig. 5A and Supporting  Fig. S4A ). We found that the hypoxia-stimulated growth of HCC cells (36) was markedly reduced by CM-272 ( Fig. 5B and Supporting Fig. S4B ). This effect was reproduced upon G9a expression knockdown, while, conversely, G9a overexpression enhanced hypoxia-stimulated cell proliferation (Supporting Fig. S4C ). Next, we examined the effects of CM-272 on the expression of key glycolytic enzymes triggered by hypoxia and also upregulated in HCC: glucose transporter-1 (GLUT1), hexokinase-2 (HK2), glucose-6-phosphate isomerase (GPI), aldolase A (ALDOA), phosphoglycerate kinase-1 (PGK1), pyruvate kinase-M2 (PKM2), and lactate dehydrogenase-A (LDHA). (37) The expression of all these genes was markedly reduced by CM-272 (Fig. 5C) , and, lactate production was consistently inhibited by CM-272 (Fig. 5D) . Hypoxia also fosters HCC development through the stimulation of angiogenesis and liver fibrosis. (38) Therefore, we evaluated the effects of CM-272 on the expression of the proangiogenic and profibrogenic factors vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGFβ). We found that CM-272 significantly inhibited hypoxia-triggered VEGF and TGFβ expression (Fig. 5E) . The key role played by G9a in VEGF and TGFβ expression was further supported by experiments in which G9a expression was knocked down (siRNA transfection) or enhanced (G9a cDNA transfection) in HCC cells (Fig. 5E ).
cM-272 INHIBIts tHe prolIFeratIoN aND actIVatIoN oF HuMaN HepatIc stellate cells
Epigenetic events control fibrogenic cell activation, and the fibrotic stroma contributes to HCC development. (39) This, together with the CM-272-mediated inhibition TGFβ and VEGF expression in HCC cells, prompted us to examine CM-272 effects on HSCs. We found that CM-272 dose-dependently inhibited the proliferation of human liver myofibroblast LX2 cells (Fig. 6A) . To better understand the effects of CM-272 in liver fibrogenic cells, we performed a microarray analysis of gene expression in LX2. We detected 1,549 up-regulated and 1,702 down-regulated genes (P < 0.01), and GO functional classification fundamentally identified categories related to HSC metabolic differentiation (e.g., vitamin A metabolism) and their response to activating stimuli (Fig. 6B) . Accordingly, when we applied GSEA, we found significant enrichment in categories associated with metabolic functions, signal transduction, and cell proliferation (Supporting Table S4 ). The positive enrichment in genes of the KEGG Retinol Metabolism gene set was particularly interesting, as was the negative enrichment in genes from the Signaling by TGFβ Receptor Complex Reactome gene set (Fig. 6C) . Upregulation of genes associated with quiescent and differentiated HSCs, such as peroxisome proliferator-activated receptor γ (PPARγ), lecithin-retinol acyltransferase (LRAT), and BMP-activin membrane-bound inhibitor (BAMBI), was validated in CM-272 treated LX2 cells and primary hHSCs (Fig. 6D) . Consistently, CM-272 treatment reduced the levels of H3K9me2 and DNA methylation at the PPARγ promoter in LX2 cells (Fig.  6E) . We also demonstrated the inhibitory effects of CM-272 on TGFβ-activated gene expression in both cell types ( Fig. 6F and Supporting Fig. S7 ).
cM-272 poteNtly INHIBIts tHe IN VIVO groWtH oF Hcc DrIVeN By lX2 cells
Activated HSCs markedly influence HCC progression; therefore, targeting the tumor-stroma crosstalk may identify improved therapeutic strategies. (40) Thus, we evaluated CM-272 antitumoral activity on xenografts in which PLC/PRF5 cells were co-injected with LX2 myofibroblasts in nude mice. As expected, growth of PLC/PRF5 tumors was significantly enhanced by LX2 cells (Fig. 7A) . CM-272 treatment resulted in a marked inhibition of PLC/PRF5-LX2 mixed tumors (Fig. 7B) . Tumor vascularization (CD31 staining) was also reduced by CM-272 ( Fig. 7C and Supporting Fig. S5A ). Consistent with our in vitro observations, CM-272 downregulated G9a expression and strongly influenced tumor cell phenotypes in vivo. Indeed, CM-272 inhibited the expression of the glycolysis driver HK2, while that of GNMT and FBP1 was upregulated (Fig. 7D) . These effects were recapitulated in xenografts generated with PLC/PRF5 cells alone (Fig. 3A and Supporting  Fig. S5B ).
Discussion
Epigenetic mechanisms are emerging as attractive therapeutic targets in solid tumors, and epigenetic drugs are already being tested in HCC clinical trials. (10) However, the extensive functional crosstalk between chromatin marks such as DNA and H3K9 methylation (13) suggests that simultaneous targeting of different epigenetic modifiers may improve therapeutic efficacy. We recently demonstrated this contention by showing the remarkable antitumoral activity of CM-272, a dual G9a/DNMT1 inhibitor, in different hematological neoplasms. (19) Now we provide evidence supporting the potential of combined G9a/DNMT1 antagonism for HCC treatment.
First, we demonstrated the coordinated overexpression of G9a and DNMT1, along with their key adaptor UHRF1, (16, 26) in human HCC tissues. The pathophysiological relevance of this matched overexpression is suggested by its significant association with molecular, histological, and clinical characteristics indicative of aggressive disease and poor prognosis. (27, 28) The rationale for the simultaneous inhibition of G9a/DNMT1 in HCC was further established by the synergistic antiproliferative action of combined G9a-and DNMT1-specific antagonists. Thus, CM-272 exerted a very potent antiproliferative effect in a wide panel of human HCC cell lines, which also showed a close correlation in the expression of G9a, DNMT1, and the UHRF1 adaptor. Interestingly, CM-272 GI 50 values found in HCC cell lines also directly correlated with the expression levels of the drug efflux pump ABCB1 (MDR1), and we demonstrated that CM-272 is a substrate for this membrane transporter. These findings suggest that inhibition of MDR1 could further enhance the therapeutic efficacy of CM-272. CM-272 inhibited HCC cells growth in vivo in the absence of apparent toxicity. The high specificity of CM-272 for G9a/DNMT1, and a mechanism of action based on the reversible inhibition of G9a and DNMT1 binding to their substrates, but not to S-adenosylmethionine, (19) may contribute to explain its lack of off-target effects and systemic toxicity.
One relevant finding was the downregulation of G9a protein levels in HCC cells and xenograft tumors upon CM-272 treatment. This response is coherent with previous studies describing the proteosomal degradation of other histone-methyltransferases (e.g., EZH2) after inhibition of their catalytic activity. (41) Reduction of G9a levels may be significant to the antitumoral effects of CM-272, as G9a has also been described as a transcriptional coactivator of cancer-related genes independent of its catalytic activity. (42) The concomitant downregulation of DNMT1 and UHRF1 proteins upon CM-272 treatment found in HCC cells could be secondary to G9a depletion, as all these proteins physically interact in multimeric functional complexes that may mediate the relative stability of their components. (13) (14) (15) (16) 18) Nevertheless, this issue merits further investigation.
The mechanisms of CM-272 antitumoral action are likely multifarious. However, the growth inhibitory effects of CM-272 on HCC cells were not accompanied by the induction of apoptosis or autophagy (data not shown). In this regard, our transcriptomic analyses provided valuable mechanistic insights. Interestingly, the downregulation of growth and proliferation-related genes was accompanied by the induction of genes characteristic of the adult and differentiated hepatocyte. The reactivation of E-cadherin expression by CM-272 may contribute to restore an epithelial and less malignant phenotype and is consistent with G9a and DNA methylation-mediated E-CAD repression in breast cancer. (43) However, perhaps more compelling was the reactivation of genes involved in central metabolic pathways, such as one-carbon metabolism and gluconeogenesis, which are epigenetically repressed during hepatocarcinogenesis. (32, 44, 45) Reprogramming of metabolism is a hallmark of neoplastic transformation, and this alteration is particularly extensive in a metabolic organ such as the liver. (37) Rewiring of glucose metabolism, including the repression of gluconeogenic enzymes and the activation of specific glycolytic isozymes, helps fulfill the tumor's anabolic demands, particularly in its hypoxic core. (37) We found that CM-272 potently counteracted these responses. Reactivation of FBP1 expression may be a key mechanism, as loss of FBP1 expression by promoter methylation activates the tumoral glycolytic program and enhances tumoral growth. (32) Moreover, FBP1 has been recently reported to directly inhibit the activity of hypoxia-inducible factors in renal cancer cells in a catalytic activity-independent manner. (46) This function of FBP1 may also be related to the overall impairment of HCC cell adaptation to hypoxia elicited by CM-272, including the blunted expression of protumorigenic factors such as VEGF and TGFβ.
Epigenetic mechanisms, including coordinated DNA and histone methylation, have emerged as central events in the transcriptomic reprogramming of quiescent to activated HSCs. (39) Our microarray analyses suggested that CM-272 returned the myofibroblastic transcriptomic phenotype of HSCs towards a more differentiated adipogenic one. (47) Although the underlying mechanisms need further elucidation, the positive effect on PPARγ expression may be significant. Indeed, PPARγ is a transcriptional suppressor of HSC fibrogenic activation, able to maintain quiescence and vitamin-A metabolism. (39) Moreover, PPARγ expression is transcriptionally silenced during HSC activation through mechanisms involving DNA and H3K9 hypermethylation, (48) and these epigenetic marks were reversed by CM-272 treatment. On the other hand, CM-272-mediated upregulation of BAMBI, a TGFβ pseudoreceptor and negative regulator of HSC activation, (49) could partially account for the blunted response to TGFβ of key fibrogenic genes. The functional relevance of these CM-272-mediated effects was demonstrated by the remarkable inhibition of the growth of mixed HCC-LX2 xenografts.
In summary, we have provided evidence supporting the therapeutic efficacy of dual G9a/DNMT1 targeting for the treatment of HCC with reversible inhibitors. Mechanistically, our study indicates that CM-272 can induce HCC and HSC cell differentiation and growth inhibition, underscoring the potential of differentiation therapy (50) in liver cancer, and provides a rationale for combination with other anticancer agents with different mechanisms of action (Fig. 8) .
